Vaccinex, Inc. (VCNX) financial statements (2021 and earlier)

Company profile

Business Address 1895 MOUNT HOPE AVE
ROCHESTER, NY 14620
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments111712395
Cash and cash equivalents111712395
Receivables0001111
Other undisclosed current assets1121010
Total current assets:1118344107
Noncurrent Assets
Property, plant and equipment0011111
Total noncurrent assets:0011111
TOTAL ASSETS:1219355117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities56877710
Accounts payable3353325
Accrued liabilities2323454
Other undisclosed current liabilities88     
Total current liabilities:1314877710
Noncurrent Liabilities
Long-term debt and lease obligation111    
Long-term debt, excluding current maturities111    
Total noncurrent liabilities:111    
Total liabilities:1415977710
Stockholders' equity
Stockholders' equity attributable to parent(27)(20)(30)(26)(26)(20)(26)
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital251251233230222222208
Accumulated deficit(277)(271)(262)(256)(249)(242)(235)
Stockholders' equity attributable to noncontrolling interest24242424242424
Total stockholders' equity:(3)4(6)(2)(2)4(2)
TOTAL LIABILITIES AND EQUITY:1219355117

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues 0   00
Cost of revenue (0)   (0)(0)
Gross profit: 0   00
Operating expenses(6)(9)(7)(7)(6)(8)(9)
Other undisclosed operating income 1     
Operating loss:(6)(9)(7)(7)(6)(8)(9)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)(0)0000
Interest and debt expense(0)(0)     
Net loss available to common stockholders, diluted:(6)(9)(7)(7)(6)(8)(9)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(6)(9)(7)(7)(6)(8)(9)
Comprehensive loss, net of tax, attributable to parent:(6)(9)(7)(7)(6)(8)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: